CoChat

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Open access
Antonia, Scott J., Balmanoukian, Ani, Brahmer, Julie, Ou, Sai-Hong I., Hellmann, Matthew D., Kim, Sang-We, Ahn, Myung-Ju, Kim, Dong-Wan, Gutierrez, Martin, Liu, Stephen V., Schöffski, Patrick, Jäger, Dirk, Jamal, Rahima, Jerusalem, Guy, Lutzky, Jose, Nemunaitis, John, Calabrò, Luana, Weiss, Jared, Gadgeel, Shirish, Bhosle, Jaishree, Ascierto, Paolo A., Rebelatto, Marlon C., Narwal, Rajesh, Liang, Meina, Xiao, Feng, Antal, Joyce, Abdullah, Shaad, Angra, Natasha, Gupta, Ashok K., Khleif, Samir N., Segal, Neil H. · 2019 · Journal of Thoracic Oncology
Cited by 97

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Durvalumab is a selective, high-affinity human immunoglobulin G1 monoclonal antibody that blocks programmed cell death ligand 1 (PD-L1) binding to programmed death 1. Here we report safety and clinical activity in the NSCLC cohort of a phase I/II trial that included multiple tumor types (Study 1108; NCT01693562). METHODS: Patients with stage IIIB-IV NSCLC (squamous or nonsquamous) received durvalumab 10 mg/kg every 2 weeks for 12 months or until confirmed progressive disease or unacceptable toxicity. Primary objectives were safety and antitumor activity. Tumoral PD-L1 expression was assessed using the VENTANA SP263 Assay. Responses were assessed by blinded independent central review (Response Evaluation Criteria in Solid Tumors v1.1). Adverse events were graded according to National Cancer Institute's Common Terminology Criteria for Adverse Events (v4.03). RESULTS: Of 304 patients, 79.0% were previously treated. Confirmed objective response rate was 21.8% in patients with greater than or equal to 25% PD-L1 expression and 6.4% in those with less than 25%; 25.9% in first-line patients and 12.7% in previously treated patients; and 14.0% in squamous and 16.7% in nonsquamous disease. Median overall survival was 12.4 months and median progression-free survival was 1.7 months; both were numerically longer in the PD-L1 greater than or equal to 25% group than in the PD-L1 less than 25% group (overall survival 16.4 versus 7.6 months, respectively; progression-free survival 2.6 versus 1.4 months, respectively). Treatment-related adverse events occurred in 57.2%, were grade 3/4 in 10.2%, and led to discontinuation in 5.6%. One patient (0.3%) died of treatment-related pneumonia with underlying pneumonitis. CONCLUSIONS: Durvalumab was clinically active irrespective of histology in this mostly pretreated population, with a manageable safety profile. Response rates and survival appeared to be enhanced in patients with greater tumoral PD-L1 expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2019.06.010

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 97

Metadata

Authors
Antonia, S. J., Balmanoukian, A., Brahmer, J., Ou, S.-H. I., Hellmann, M. D., Kim, S.-W., Ahn, M.-J., Kim, D.-W., Gutierrez, M., Liu, S. V., Schöffski, P., Jäger, D., Jamal, R., Jerusalem, G., Lutzky, J., Nemunaitis, J., Calabrò, L., Weiss, J., Gadgeel, S., Bhosle, J., Ascierto, P. A., Rebelatto, M. C., Narwal, R., Liang, M., Xiao, F., Antal, J., Abdullah, S., Angra, N., Gupta, A. K., Khleif, S. N., & Segal, N. H.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2019-10
Volume
14
Issue
10
Pages
1794-1806
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2952953974
Cited by
97
References
7
FWCI
5.62
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.